Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To test the noninferiority of cetuximab administered every 2 weeks (Q2W) versus once weekly (Q1W) in treating metastatic colorectal cancer (mCRC) with regard to overall survival (OS). Patients: Patients receiving cetuximab plus chemotherapy for mCRC in a line-agnostic setting. Methods: This cohort study in IBM MarketScan followed patients from initiation of cetuximab for mCRC until the end of the data availability period, proxy-based death or loss of insurance coverage for >30 days. Results: The hazard ratio for OS was 0.94 (0.85–1.03), and the inferiority hypothesis was rejected at p < 0.001. No significant differences were noted in rates of safety events between Q2W and Q1W. Conclusion: Our real-world study confirmed the noninferiority of cetuximab administered Q2W versus Q1W for OS.
Supplementary Material
File (supplementary materials.docx)
- Download
- 1.42 MB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
WHO. Colorectal cancer (2019). https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
2.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16(12), 713–732 (2019).
3.
Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70(3), 145–164 (2020).
4.
Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1), 3–27 (2004).
5.
Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J. Gastroenterol. 21(41), 11767–11776 (2015).
6.
Siegel RL, Miller KD, Fedewa SA et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67(3), 177–193 (2017).
7.
National Comprehensive Cancer Network. Colon cancer (Version 4.2020). NCCN (2020). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
8.
National Comprehensive Cancer Network. Rectal cancer (Version 6.2020) (2020). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
9.
García-Foncillas J, Sunakawa Y, Aderka D et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front. Oncol. 9, 849 (2019).
10.
Dekker E, Tanis PJ, Vleugels JLA et al. Colorectal cancer. Lancet 394(10207), 1467–1480 (2019).
11.
Erbitux (cetuximab). Prescribing information (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
12.
Erbitux, INN-cetuximab. Summary of product characteristics (2009). https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf
13.
Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337–345 (2004).
14.
Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311–2319 (2008).
15.
Wilke H, Glynne-Jones R, Thaler J et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J. Clin. Oncol. 26(33), 5335–5343 (2008).
16.
Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663–671 (2009).
17.
Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408–1417 (2009).
18.
Tabernero J. Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13(2), 113–119 (2008).
• Derived the pharmacokinetics of cetuximab 250 mg/m2 Q1W vs 500 mg/m2 Q2W from 19 clinical studies of patients with various solid tumor types, including colorectal cancer (CRC).
19.
National Institute for Health and Care Excellence. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (2017). https://www.nice.org.uk/Guidance/ta439
20.
Phelip JM, Tougeron D, Léonard D et al. Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 51(10), 1357–1363 (2019).
21.
Song X, Zhao Z, Barber B et al. Characterizing medical care by disease phase in metastatic colorectal cancer. Am. J. Manag. Care 17(Suppl. 5 Developing), SP20–SP25 (2011).
• Defines an algorithm used to define a proxy for death based on an assessment of patterns and costs of medical care by phase of metastatic CRC disease.
22.
Foley KA, Wang PF, Barber BL et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann. Oncol. 21(7), 1455–1461 (2010).
• Describes incidence rates of cetuximab-related infusion reactions requiring medical intervention in clinical practice.
23.
Rothmann M, Li N, Chen G, Chi GY et al. Design and analysis of non-inferiority mortality trials in oncology. Stat. Med. 22(2), 239–264 (2003).
•• Presents noninferiority analyses that do not require a fixed margin, but rather compare 95% two-sided confidence intervals to assess differences between the treatment and the control.
24.
Van Helden EJ, Menke-van der Houven van Oordt CW, Heymans MW et al. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer Metastasis Rev. 36(2), 395–406 (2017).
• Comprehensive meta-analysis of 17 randomized clinical trials to determine the optimal use of anti-EGFR antibodies for the treatment of metastatic CRC.
25.
Schneeweiss S, Rassen JA, Glynn RJ et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20(4), 512–522 (2009).
• Describes a high-dimensional propensity score to improve effect estimates compared with adjustment using predefined covariates.
26.
Erbitux (cetuximab). Prescribing information (2012). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf
27.
Blumenthal GM, Gong Y, Kehl KL et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann. Oncol. 30(5), 830–838 (2019).
28.
Gong Y, Kehl KL, Oxnard GR et al. Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): a pooled analysis of 8 trials. J. Clin. Oncol. 36(Suppl. 15), 9064–9064 (2018).
29.
Hari P, Romanus D, Palumbo A et al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. Clin. Lymphoma Myeloma Leuk. 18(2), 152–160 (2018).
30.
Brodowicz T, Ciuleanu TE, Radosavljevic D et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized Phase II CECOG study. Ann. Oncol. 24(7), 1769–1777 (2013).
31.
Mrabti H, De la Fouchardiere C, Desseigne F et al. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J. Cancer Res. Ther. 5(4), 272–276 (2009).
32.
Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann. Oncol. 19(6), 1141–1145 (2008).
33.
Yeh Y, Chiang C, Chem C et al. Efficacy and safety of weekly and biweekly cetuximab-combined FOLFIRI regimen as first-line setting in patients with metastatic colorectal cancer: experience in a southern Taiwan medical center. J. Soc. Colon Rectal Surgeon (Taiwan). 21, 59–68 (2010).
34.
Yu Y, Zhang W, Sun Y et al. FOLFOX/XELOX plus cetuximab administered weekly versus biweekly as a first-line treatment for patients with KRAS/RAS wild-type metastatic colorectal cancer: a retrospective study. Chinese J. Clin. Oncol. 32, 105 (2018).
35.
Kasper S, Cheng A, Overkamp F et al. Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer. Ann. Oncol. 30(Suppl. 5), v220–v221 (2019).
• Pooled analysis of patient-level data from five primary data collection studies demonstrating noninferiority of cetuximab Q2W to Q1W in a 1L setting.
36.
Matsuda A, Yamada T, Jamjittrong S et al. Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis. Anticancer Res. 40(6), 3469–3476 (2020).
Information & Authors
Information
Published In
Pages: 1117 - 1129
PubMed: 33118841
Copyright
© 2020 Merck KGaA, Darmstadt, Germany. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 30 June 2020
Accepted: 4 September 2020
Published online: 29 October 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0132
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil, Joel Guigay, Stefan Kasper, Per Pfeiffer, Carmine Pinto, Kensei Yamaguchi, Takayuki Yoshino, Christoph Zielinski, Regina Esser, Josep Tabernero, Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule, Future Oncology, 10.2217/fon-2023-0282, 20, 7, (393-407), (2023).
- Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui, Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer, Journal of Comparative Effectiveness Research, 10.2217/cer-2022-0143, 12, 2, (2023).
- Liang Zhang, He Li, TianFu Wang, RuiXin Wang, Long Cheng, Gang Wang, Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery, Cancers, 10.3390/cancers14215408, 14, 21, (5408), (2022).
- Chris P Pescott, Emmanuelle Boutmy, Michael Batech, Philippe Ronga, Francois-Xavier Lamy, Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer, Journal of Comparative Effectiveness Research, 10.2217/cer-2020-0232, 10, 5, (353-364), (2021).